CTLA4 and type 1 diabetes mellitus: A clinical trial of the CTLA-4-Ig molecule abatacept, given at days 1, 14 and 28 and then monthly for 2 years in individuals with recent-onset stage 3 T1D, has shown a reduced decline in C-peptide levels compared with placebo178,179.